Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations Jul 30, 2026 · Cris Tolomia Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates Read more »